Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings
Shares of Merck & Co slipped 0.2% to $110.75 on Thursday, fluctuating within a range of $108.48 to $111.06 during the day.
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings
Merck & Co shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading.
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom
Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%.
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda
Merck & Co boosted its long-term revenue forecast for several new products and pipeline candidates, projecting $70 billion from these “new growth drivers” by the mid-2030s. The company raised its cardiometabolic and respiratory sales outlook to around $20 billion, up from $15 billion, while its infectious-disease forecast jumped to about $15 billion from $5 billion. Merck shares slipped 1.2% to close at $109.19 on Monday. Meanwhile, Johnson & Johnson climbed 2.6%, Eli Lilly added 1.6%, and Pfizer dropped 0.8%.
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk
Merck & Co shares slipped $1.26, or 1.1%, to $109.27 in Monday afternoon trading. The stock has fluctuated between $111.45 and $108.95 today.
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next
Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday's premarket session.
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion
Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch
Merck & Co., Inc. shares closed down 0.4% on Friday at $110.53, and traders head into Monday with takeover chatter back in the tape. The Wall Street Journal reported Merck is in talks to buy Revolution Medicines in a deal valued around $28 billion to $32 billion.
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK
Merck & Co closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion.
Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal
Cisco Systems shares slipped 0.1% to close at $73.88 on Friday, as investors digested the news that the U.S. Supreme Court agreed to hear the company’s appeal in a lawsuit involving China and the Falun Gong spiritual movement. During the session, the stock fluctuated between $73.17 and $74.33.
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus
Merck & Co shares slipped on Friday following reports that the pharma giant is in talks to acquire cancer-focused biotech Revolution Medicines for as much as $32 billion. Merck ended the day down 0.4% at $110.53, after swinging between $110.26 and $112.46.
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod
Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares.
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play
Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday after the Financial Times report, which said talks were not final and could still take weeks, with other large drugmakers still circling; Merck and Revolution did not respond to requests for comment. The potential acquisition would be the biggest in the sector since Pfizer’s $43 billion Seagen deal and would add Revolution’s late-stage RAS cancer drug candidate daraxonrasib; Mizuho analysts estimate Revolution’s RAS inhibitors could generate more than $10 billion in risk-adjusted sales by 2035 as Merck looks past Keytruda patent expiries later this decade.
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger
Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed.
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes
Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus
Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
Merck stock in focus after CDC rewrites childhood vaccine schedule, puts Gardasil dosing under a microscope
Merck & Co. shares rose 1.3% to $108.87 on Tuesday, after U.S. health officials overhauled the childhood immunization schedule and shifted several vaccines away from broad, routine recommendations.
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Merck & Co shares rose about 1.1% to $108.60 in afternoon trading on Tuesday and earlier hit a 52-week high of $110.16. The broader S&P 500 and the Health Care Select Sector SPDR Fund were also higher.
Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight
Merck & Co shares dipped in late trading on Monday after U.S. health officials rewrote the childhood and adolescent immunization schedule, including a change to a one-dose recommendation for the human papillomavirus vaccine. Merck closed up 0.93% at $107.44 and was last down 0.22% at $107.20 after the bell. Yahoo Finance
TechStock² Updates
